

Aimovig - Resources - HCP

[Prescribing information](#)

Image



Image



Aimovig® (erenumab) resources


Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.¹

Explore the resources below, which contain useful information on Aimovig that you can share with your patients, in order to help them understand their treatment.

You can download certain files below. In order to do this, you will be required to register.

Please do not share links to this website or screenshots with patients, as this website is intended for healthcare professionals only.

Image



Your guide to Aimovig

PDF

[Download](#)

Your guide to Aimovig®

A guide for patients prescribed Aimovig to provide them with important information about what Aimovig is, who it is for, how it works and what to expect during treatment.

Reference

1. Aimovig® (erenumab) Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

<https://www.pro.novartis.com/uk-en/medicines/neuroscience/aimovig/resources>